Quantifying the CDK inhibitor VMY-1-103’s activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI

The development of new small molecule-based therapeutic drugs requires accurate quantification of drug bioavailability, biological activity and treatment efficacy. Rapidly measuring these endpoints is often hampered by the lack of efficient assay platforms with high sensitivity and specificity. Usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirajuddin, Paul, Das, Sudeep, Ringer, Lymor, Rodriguez, Olga C., Sivakumar, Angiela, Lee, Yi-Chien, Üren, Aykut, Fricke, Stanley T., Rood, Brian, Ozcan, Alpay, Wang, Sean S., Karam, Sana, Yenugonda, Venkata, Salinas, Patricia, Petricoin III, Emanuel, Pishvaian, Michael, Lisanti, Michael P., Wang, Yue, Schlegel, Richard, Moasser, Bahram, Albanese, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495823/
https://www.ncbi.nlm.nih.gov/pubmed/22983062
http://dx.doi.org/10.4161/cc.21988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495823/
https://www.ncbi.nlm.nih.gov/pubmed/22983062
http://dx.doi.org/10.4161/cc.21988

Ejemplares similares